Interventions, especially pharmacotherapy seemed to improve certain aspects of cognition and increase circulating BDNF levels.<h4>Conclusion</h4>Circulating BDNF alone does not seem to be a valid biomarker of cognitive dysfunction in patients with disorders on the schizophrenia-bipolar spectrum, owing to several confounding factors. The gene discussed is BDNF; the disease is schizophrenia.